A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Clinical trial NCT06925737 · RECRUITING

Trial details

NCT number: NCT06925737
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Prostate Cancer Prostatic Neoplasms

Start date: 2025-05-13
Primary completion: 2028-06-26
Enrollment: 1440

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.